Concepedia

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

Michael Wang, Hun Ju Lee, Hubert H. Chuang, Nicolaus A. Wagner‐Bartak, Frederick Hagemeister, Jason R. Westin, Luis Fayad, Felipe Samaniego, Francesco Turturro, Yasuhiro Oki,

The Lancet Oncology · 2015 · 214 citations · 24 references

DOI

Concepts

References

24

Revised Response Criteria for Malignant Lymphoma

Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text

, , +15

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

, , +17

The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins.

C Schlüter, M. Duchrow, Claudia Wohlenberg et al. · The Journal of Cell Biology · 1993 · 776 citations · Full text

, , +10

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

Sabine Ponader, Shih‐Shih Chen, Joseph J. Buggy et al. · Blood · 2011 · 635 citations · Full text

, , +15

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

Martin F. M. de Rooij, Annemieke Kuil, Christian R. Geest et al. · Blood · 2012 · 553 citations · Full text

, , +13